SG3 Management’s Axsome Therapeutics AXSM Stock Holding History

SG3 Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,000	Closed	-$330K	–	1039
2021 Q3	$330K	Buy	+10,000	New	+$390K	0.01%	688

Other funds holding AXSM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG3 Management's AXSM Position: Q1 2023 in Review

SG3 Management sold out of Axsome Therapeutics (AXSM) in Q1 2023, closing a stake of 12,000 shares — an estimated $926K sold.

SG3 Management first reported a position in AXSM in Q2 2022 and held it in 2 quarters. The position peaked at $926K in Q4 2022. 197 funds tracked by Wall St. Rank hold AXSM as of Q1 2023.

SG3 Management reported no remaining Axsome Therapeutics position as of Q1 2023 after selling out during the quarter.
SG3 Management sold 12,000 Axsome Therapeutics shares in Q1 2023, an estimated $926K.
SG3 Management first reported a position in Axsome Therapeutics in Q2 2022 and held it in 2 quarters.
SG3 Management's Axsome Therapeutics position peaked at $926K in Q4 2022.
197 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.